GOG-3015/YO39523 Atezolizumab vs. Placebo with Paclitaxel + Carboplatin + Bevacizumab in Ovarian, Fallopian Tube, PPC

Grants and Contracts Details


TITLE: A PHASE Ill, MUL TICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB FOR PATIENTS WITH NEWLY-DIAGNOSED STAGE Ill OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER Objectives and Endpoints This study will evaluate the efficacy, safety, and pharmacokinetics of atezolizumab administered with paclitaxel+carboplatin+bevacizumab compared with placebo+ paclitaxel+carboplatin+ bevacizumab in patients with newly-diagnosed, untreated ovarian, fallopian tube, and/or primary peritoneal cancer.
Effective start/end date11/29/177/13/23


  • Gynecological Oncology Group Foundation Incorporated: $272,309.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.